Memantine in Moderate-to-Severe Alzheimer Disease Evidence and Ethics Based? [1] (multiple letters)

Alzheimer Disease and Associated Disorders

Volumn 18, Issue 1, 2004, Pages 47-48

  Rikkertt, Marcel G M Olde ^a   Dekkers, Wim J M ^a   Scheltens, Philip ^b   Verhey, Frans ^c   Reisberg, Barry ^d   Stöffler, Albrecht ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

ALZHEIMER DISEASE; CAREGIVER; COGNITION; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; HUMAN; LETTER; MEDICAL ETHICS; OUTCOMES RESEARCH; PRIORITY JOURNAL;

ALZHEIMER DISEASE; CLINICAL TRIALS; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEDICAL FUTILITY; MEMANTINE; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX;

EID: 1542314312     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200401000-00010     Document Type: Letter

References (0)